QQQ

DIA

SPY

TLT

GLD

BTC/USD

QQQ

DIA

SPY

TLT

GLD

BTC/USD

Aducanumab

Biogen Gets FDA Nod For Controversial Alzheimer's Drug; First Treatment Approval For The Disease In 18 Years

Biogen Gets FDA Nod For Controversial Alzheimer's Drug; First Treatment Approval For The Disease In 18 Years

After months of wait, Biogen Inc. (NASDAQ: BIIB) has finally achieved success by taking its controversial Alzheimer's treatment past the finish line.

Jun 7, 2021, 11:37 AM

Biogen Shares Jump After FDA Delays Aducanumab Decision By 3 Months

Biogen Shares Jump After FDA Delays Aducanumab Decision By 3 Months

Biogen Inc (NASDAQ: BIIB) shares are up sharply Friday after the company announced a delay in the FDA decision for its Alzheimer's treatment candidate, aducanumab.

Jan 29, 2021, 9:15 AM

Analysts Predict Volatility In Biogen Shares Until March 2021

Analysts Predict Volatility In Biogen Shares Until March 2021

Wall Street analysts suggest that Biogen Inc (NASDAQ: BIIB) stock is about to see a significant selloff and could witness volatility until the Food and Drugs Ad

Nov 9, 2020, 5:51 AM

Biogen's Aducanumab Fails To Win FDA Panel Backing

Biogen's Aducanumab Fails To Win FDA Panel Backing

Biogen Inc (NASDAQ: BIIB) failed to win the backing of the FDA panel which reviewed the BLA for its controversial Alzheimer's drug aducanumab, an antibody which targets amyloid-beta.

Nov 6, 2020, 5:04 PM

Biogen Surges Higher On Favorable FDA Briefing Doc For Alzheimer's Candidate

Biogen Surges Higher On Favorable FDA Briefing Doc For Alzheimer's Candidate

Biogen Inc (NASDAQ: BIIB) shares were soaring Wednesday in reaction to an FDA briefing document released ahead of Friday's Adcom meeting on the investigational Alzheimer's drug aducanumab, an amyloid beta-targeting antibody.

Nov 4, 2020, 11:48 AM